Evaluation of a new quantitative point-of-care test platform for urine-based detection of bladder cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 3, 2014, Pages 337-344

  Ritter, Rene ^a   Hennenlotter, Jörg ^a   Kühs, Ursula ^a   Hofmann, Udo ^a   Aufderklamm, Stefan ^a   Blutbacher, Pia ^a   Deja, Angelika ^a   Hohneder, Andrea ^a   Gerber, Valentina ^a   Gakis, Georgios ^a   Stenzl, Arnulf ^a   Schwentner, Christian ^a   Todenhöfer, Tilman ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Bladder cancer; Cytology; NMP22; Point of care; Surveillance; UBC rapid; Urine markers

Indexed keywords

NUCLEAR MATRIX PROTEIN 22; TUMOR ANTIGEN; UNCLASSIFIED DRUG; URINE BLADDER CANCER ANTIGEN; CYTOKERATIN 18; CYTOKERATIN 8; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER CANCER DETECTION KIT; CANCER ELISA KIT; CLINICAL EVALUATION; CYSTOSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NUCLEAR MATRIX PROTEIN22 BLADDERCHEK TEST; POINT OF CARE TESTING; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; TUMOR MARKER RAPID TEST; URINALYSIS; URINE BLADDER CANCER ANTIGEN RAPID POINT OF CARE TESTING SYSTEM; URINE CYTOLOGY; VERY ELDERLY; YOUNG ADULT; CARCINOMA, TRANSITIONAL CELL; HOSPITAL INFORMATION SYSTEM; URINARY BLADDER NEOPLASMS; URINE;

CARCINOMA, TRANSITIONAL CELL; HUMANS; KERATIN-18; KERATIN-8; POINT-OF-CARE SYSTEMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84897076738     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.09.024     Document Type: Article

References (31)

1. Todenhofer T., Hennenlotter J., Kuhs U., et al. Influence of urinary tract instrumentation and inflammation on the performance of urine markers for the detection of bladder cancer. Urology 2012, 79:620-624.
2. Wiener H.G., Mian C., Haitel A., Pycha A., Schatzl G., Marberger M. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer?. J Urol 1998, 159:1876-1880.
3. Mian C., Lodde M., Haitel A., Egarter Vigl E., Marberger M., Pycha A. Comparison of two qualitative assays, the UBC rapid test and the BTA stat test, in the diagnosis of urothelial cell carcinoma of the bladder. Urology 2000, 56:228-231.
4. Todenhofer T., Hennenlotter J., Esser M., et al. Combined application of cytology and molecular urine markers to improve the detection of urothelial carcinoma. Cancer Cytopathol 2013, 121:252-260.
5. Banek S., Schwentner C., Tager D., et al. Prospective evaluation of fluorescence-in situ-hybridization to detect bladder cancer: results from the UroScreen-Study. Urol Oncol 2012, May 22. [Epub ahead of print].
6. Youssef R.F., Schlomer B.J., Ho R., Sagalowsky A.I., Ashfaq R., Lotan Y. Role of fluorescence in situ hybridization in bladder cancer surveillance of patients with negative cytology. Urol Oncol 2012, 30:273-277.
7. Soloway M.S., Briggman V., Carpinito G.A., et al. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 1996, 156(2 Pt 1):363-367.
8. Sanchez-Carbayo M., Herrero E., Megias J., et al. Initial evaluation of the diagnostic performance of the new urinary bladder cancer antigen test as a tumor marker for transitional cell carcinoma of the bladder. J Urol 1999, 161:1110-1115.
9. Papanicolaou G.N., Marshall V.F. Urine sediment smears as a diagnostic procedure in cancers of the urinary tract. Science 1945, 101:519-520.
10. Layfield L.J., Elsheikh T.M., Fili A., Nayar R., Shidham V. Review of the state of the art and recommendations of the Papanicolaou Society of Cytopathology for urinary cytology procedures and reporting: the Papanicolaou Society of Cytopathology Practice Guidelines Task Force. Diagn Cytopathol 2004, 30:24-30.
11. Babjuk M., Oosterlinck W., Sylvester R., et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011, 59:997-1008.
12. Hall M.C., Chang S.S., Dalbagni G., et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007, 178:2314-2330.
13. Soloway MKS. Bladder Cancer. ICUD Guidelines. 2nd ed. ICUD; 2012. p. 27.
14. Cha E.K., Tirsar L.A., Schwentner C., et al. Immunocytology is a strong predictor of bladder cancer presence in patients with painless hematuria: a multicentre study. Eur Urol 2012, 61:185-192.
15. Friedrich M.G., Hellstern A., Hautmann S.H., et al. Clinical use of urinary markers for the detection and prognosis of bladder carcinoma: a comparison of immunocytology with monoclonal antibodies against Lewis X and 486p3/12 with the BTA STAT and NMP22 tests. J Urol 2002, 168:470-474.
16. Smrkolj T., Mihelic M., Sedlar A., Sterle I., Osredkar J., Sedmak B. Performance of nuclear matrix protein 22 urine marker and voided urine cytology in the detection of urinary bladder tumors. Clin Chem Lab Med 2011, 49:311-316.
17. Coskuner E., Cevik I., Ozkan A., Dillioglugil O., Akdas A. In the cystoscopic follow-up of non-muscle-invasive transitional cell carcinoma, NMP-22 works for high grades, but unreliable in low grades and upper urinary tract tumors. Int Urol Nephrol 2012, 44:793-798.
18. May M., Hakenberg O.W., Gunia S., et al. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice. Urology 2007, 70:449-453.
19. Shariat S.F., Casella R., Wians F.H., et al. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology. Eur Urol 2004, 45:304-313. [author reply 13].
20. Todenhofer T., Hennenlotter J., Aufderklamm S., et al. Individual risk assessment in bladder cancer patients based on a multi-marker panel. J Cancer Res Clin Oncol 2013, 139:49-56.
21. Hakenberg O.W., Fuessel S., Richter K., et al. Qualitative and quantitative assessment of urinary cytokeratin 8 and 18 fragments compared with voided urine cytology in diagnosis of bladder carcinoma. Urology 2004, 64:1121-1126.
22. Schroeder G.L., Lorenzo-Gomez M.F., Hautmann S.H., et al. A side by side comparison of cytology and biomarkers for bladder cancer detection. J Urol 2004, 172:1123-1126.
23. Babjuk M., Soukup V., Pesl M., et al. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma. Urology 2008, 71:718-722.
24. Todenhofer T., Hennenlotter J., Esser M., et al. Combined application of cytology and molecular urine markers to improve the detection of urothelial carcinoma. Cancer Cytopathol 2013, 121:252-260.
25. Huber S., Schwentner C., Taeger D., et al. Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study. BJU Int 2012, 110:699-708.
26. Boman H., Hedelin H., Holmang S. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. J Urol 2002, 167:80-83.
27. Todenhofer T., Hennenlotter J., Tews V., et al. Impact of different grades of microscopic hematuria on the performance of urine-based markers for the detection of urothelial carcinoma. Urol Oncol 2011, [Epub ahead of print].
28. Shariat S.F., Karam J.A., Lotan Y., Karakiewizc P.I. Critical evaluation of urinary markers for bladder cancer detection and monitoring. Rev Urol 2008, 10:120-135.
29. Lotan Y., Capitanio U., Shariat S.F., Hutterer G.C., Karakiewicz P.I. Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection. BJU Int 2009, 103:1368-1374.
30. Yoder B.J., Skacel M., Hedgepeth R., et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol 2007, 127:295-301.
31. Babjuk M., Oosterlinck W., Sylvester R., et al. EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 Update. Eur Urol 2011, 59:997-1008.